EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy

Zhiang Liu, Ying Chen, Yulin Cao, Yanchao Zhang, Yuanben Wang, Han Cheng, Junhui Tang, Haofei Hong, Yuyang Feng, Surui Yao, Zehua Bian iD, Yuan Yin iD und 3 weitere

Journal of Extracellular Vesicles · 2026

DOI: 10.1002/jev2.70236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Zhiang Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Tumor-Associated Macrophages, Nanomedicine, Single-Domain Antibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Social Development Key Project of Jiangsu Province, Wuxi Medical Key Discipline, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour development and progression are driven by intricate interactions among various cell types within the tumour microenvironment (TME). Targeting a single cell type often fails to eradicate cancer, highlighting the need for strategies to co‐target multiple cell types. MicroRNA‐21‐5p, highly abundant in tumour cells and tumour‐associated macrophages (TAMs), exerts strong cancer‐promoting effects. Epidermal growth factor receptor (EGFR) is overexpressed in various cancer types, and programmed death‐ligand 1 (PD‐L1) is expressed predominantly by TAMs in multiple cancers. In this study, we developed a dual‐targeted engineered milk‐derived extracellular vesicles system (7D12/KN035‐iEVs), decorated with 7D12 (an EGFR nanobody) and KN035 (a PD‐L1 nanobody), to specifically deliver miR‐21‐5p inhibitors into EGFR + and/or PD‐L1 + tumour cells and TAMs, thereby inhibiting tumour progression while reprogramming immunosuppressive TME. Notably, this dual‐targeting nanomedicine synergistically inhibits tumour growth when combined with immunotherapy and radiotherapy. In summary, this mEV‐based nanomedicine represents a promising universal strategy for cancer treatment, offering a versatile platform for targeting multiple components of the TME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesTumor-Associated MacrophagesNanomedicineSingle-Domain AntibodiesMilkNeoplasmsAnimalsMicroRNAsErbB ReceptorsHumansTumor MicroenvironmentMiceB7-H1 AntigenCell Line, TumorFemaleImmunotherapy

Stichwörter der Autor:innen

EGFRPD‐L1miR‐21‐5pmilk‐derived extracellular vesiclenanobodytumour‐associated macrophage

Substanzen

MicroRNAsErbB ReceptorsSingle-Domain AntibodiesB7-H1 Antigen

Autor:innen und Institutionen

  • Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
  • Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
  • Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu, China.

ORCID-Profile: Zehua Bian, Yuan Yin, Kaisa Cui, Zhimeng Wu, Zhaohui Huang

Förderung

  • Social Development Key Project of Jiangsu Province
  • Wuxi Medical Key Discipline
  • National Natural Science Foundation of China
  • Medical Key Strategic Project of Wuxi Health Commission
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • Key Industry Talents of "333" Projects of Jiangsu Province

Zitieren

APA

Liu, Z., Chen, Y., Cao, Y., Zhang, Y., Wang, Y., Cheng, H., Tang, J., Hong, H., Feng, Y., Yao, S., Bian, Z., Yin, Y., Cui, K., Wu, Z., & Huang, Z. (2026). A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70236

Vancouver

Liu Z, Chen Y, Cao Y, Zhang Y, Wang Y, Cheng H, et al. A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70236

BibTeX
@article{Liu2026,
  author = {Liu, Zhiang and Chen, Ying and Cao, Yulin and Zhang, Yanchao and Wang, Yuanben and Cheng, Han and Tang, Junhui and Hong, Haofei and Feng, Yuyang and Yao, Surui and Bian, Zehua and Yin, Yuan and Cui, Kaisa and Wu, Zhimeng and Huang, Zhaohui},
  title = {A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  doi = {10.1002/jev2.70236}
}
Kostenlos starten →